Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Primary Objective:

* To assess the tolerability at global doses

Secondary Objectives:

* Safety
* Pharmacokinetics
* Efficacy
Prostate Cancer
DRUG: Cabazitaxel (XRP6258)|DRUG: prednisolone
Identification of maximum tolerated dose, up to 18 months
number of participants with treatment emergent adverse events, up to 18 months|Pharmakokinetic parameters of Cabazitaxel, up to 18 months|Prostate Specific Antigen (PSA) Response, up to 18 months
The duration of screening within 28 days, treatment 3 weeks/cycle and follow-up 30 days after the last cabazitaxel administration.